Brain injection trial hopes to tame Parkinson's
NCT ID NCT05822739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a gene therapy called BBM-P002 in 10 people with advanced Parkinson's disease. The treatment is given as a single injection directly into the brain during a neurosurgical procedure. The main goal was to check safety, but researchers also looked for signs of improvement in symptoms and medication use. Because it is a very small, early trial, results are preliminary and cannot yet confirm whether the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BBM-P002 (a gene therapy injected into the brain)
What this could lead to
If it works, this could point toward a new way to control Parkinson's symptoms and reduce medication needs.
What could go wrong
This is a very early, small study with only 10 people. It is designed mainly to check safety, not prove effectiveness. The treatment involves brain surgery, which carries risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China